Journal Section:
Editor's choice
References
1.
Empfehlungen Gynäkologische Onkologie Kommission Mamma, 2021. www.ago-online.org.
2.
3.
Ishihara
BP
, Farah
D
, Fonseca
MCM
, Nazario
A
. The risk of developing breast, ovarian, and endometrial cancer in obese women submitted to bariatric surgery: a meta-analysis
. Surg Obes Relat Dis
. 2020 Oct
;16
(10
):1596
–602
.http://dx.doi.org/10.1016/j.soard.2020.06.008.<!–Q1: last-page details fetched from PubMed–>4.
Cao
Y
, Tan
A
. Aspirin might reduce the incidence of breast cancer: an updated meta-analysis of 38 observational studies
. Medicine (Baltimore)
. 2020 Sep
;99
(38):e21917
.5.
Peng
R
, Liang
X
, Zhang
G
, Yao
Y
, Chen
Z
, Pan
X
, . Association use of bisphosphonates with risk of breast cancer: a meta-analysis
. Biomed Res Int
. 2020 Oct
;2020
:5606573
.6.
Yadav
S
, Hu
C
, Hart
SN
, Boddicker
N
, Polley
EC
, Na
J
, . Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer
. J Clin Oncol
. 2020
;38
:1409
–18
.http://dx.doi.org/10.1200/JCO.19.02190.13<!–Q2: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, stl, last-page details fetched from PubMed–>7.
Tung
NM
, Robson
ME
, Ventz
S
, Santa-Maria
CA
, Nanda
R
, Marcom
PK
, . TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
. J Clin Oncol
. 2020 Dec
;38
(36
):4274
–82
.http://dx.doi.org/10.1200/JCO.20.02151.<!–Q3: first-page, last-page details fetched from PubMed–>8.
Breast Cancer Association Consortium
, Dorling
L
, Carvalho
S
, Allen
J
, González-Neira
A
, Luccarini
C
, Wahlström
C
, . Breast cancer risk genes – association analysis in more than 113,000 Women
. N Engl J Med
. 2021 Feb
;384
(5
):428
–39
.http://dx.doi.org/10.1056/NEJMoa1913948.<!–Q4: author2surname, author2initial, author3surname, author3initial, author4surname, author4initial, author5surname, author5initial, author6surname, last-page details fetched from PubMed–>9.
Co
M
, Liu
T
, Leung
J
, Li
CH
, Tse
T
, Wong
M
, . Breast conserving surgery for BRCA mutation carriers – a systematic review
. Clin Breast Cancer
. 2020 Jun
;20
(3
):e244
–50
.http://dx.doi.org/10.1016/j.clbc.2019.07.014.<!–Q5: last-page details fetched from PubMed–>10.
Yoon
KH
, Chae
S
, Kang
E
, Shin
HC
, Kim
JH
, Kim
IA
, . Contralateral breast cancer and ipsilateral breast tumor recurrence in BRCA1/2 carriers and non-carriers at high-risk of hereditary breast cancer
. J Breast Cancer
. 2019 Sep
;22
(4
):587
–98
.http://dx.doi.org/10.4048/jbc.2019.22.e47.<!–Q6: atl, last-page details fetched from PubMed–>12.
Alabousi
M
, Wadera
A
, Kashif Al-Ghita
M
, Al-Ghetaa
RK
, Salameh
JP
, Pozdnyakov
A
, . Performance of digital breast tomosynthesis, synthetic mammography and digital mammography in breast cancer screening: a systematic review and meta-analysis
. J Natl Cancer Inst
. 2020
doi: 10.1093/jnci/djaa205. Online ahead of print.http://dx.doi.org/10.1093/jnci/djaa205.13.
Phi
XA
, Tagliafico
A
, Houssami
N
, Greuter
MJW
, de Bock
GH
. Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts – a systematic review and meta-analysis
. BMC Cancer
. 2018 Apr
;18
(1
):380
.14.
Bakker
MF
, de Lange
SV
, Pijnappel
RM
, Mann
RM
, Peeters
PHM
, Monninkhof
EM
, . Supplemental MRI screening for women with extremely dense breast tissue
. N Engl J Med
. 2019 Nov
;381
(22
):2091
–2102
.15.
Dromain
C
, Vietti-Violi
N
, Meuwly
JY
. Angiomammography: a review of current evidences.
Diagn Interv Imaging.
2019 Oct
;100
(10
):593
–605
.16.
Mariscotti
G
, Durando
M
, Tagliafico
A
, Campanino
PP
, Bosco
D
, Casella
C
, . Preoperative breast cancer staging with multi-modality imaging and surgical outcomes
. Eur J Radiol
. 2020 Jan
;122
:108766
.17.
Deyarmin
B
, Kane
JL
, Valente
AL
, van Laar
R
, Gallagher
C
, Shriver
CD
, . Effect of ASCO/CAP guidelines for determining ER Status on molecular subtype
. Ann Surg Oncol
. 2013 Jan
;20(1)
:87
–93
.18.
Smith
I
, Robertson
J
, Kilburn
L
, Wilcox
M
, Evans
A
, Holcombe
C
, . Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
. Lancet Oncol
. 2020 Nov
;21
(11
):1443
–54
.http://dx.doi.org/10.1016/S1470-2045(20)30458-7.<!–Q11: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>19.
Nitz
U
, Gluz
O
, Kreipe
HH
, Christgen
M
, Kuemmel
S
, Baehner
FL
, . The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
. Ther Adv Med Oncol
. 2020 Nov
;12
:1758835920973130
.http://dx.doi.org/10.1177/1758835920973130.<!–Q12: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial details fetched from PubMed–>20.
Dowsett
M
, Ellis
MJ
, Dixon
JM
, Gluz
O
, Robertson
J
, Kates
R
, . Evidence-based guidelines for managing patients with primary ER+ HER2– breast cancer deferred from surgery due to the COVID-19 pandemic
. NPJ Breast Cancer
. 2020 Jun
;6
:21
.http://dx.doi.org/10.1038/s41523-020-0168-9.<!–Q7: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial details fetched from PubMed–>21.
Schmid
P
, Adams
S
, Rugo
HS
, Schneeweiss
A
, Barrios
CH
, Iwata
H
, . Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer
. N Engl J Med
. 2018
;379
(22
):2108
–21
.http://dx.doi.org/10.1056/NEJMoa1809615.<!–Q8: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, iss, last-page details fetched from PubMed–>22.
Noske
A
, Ammann
JU
, Wagner
DC
, Denkert
C
, Lebeau
A
, Sinn
P
, . A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer
. Histopathology
. 2021 Mar;78(4):567–77
. http://dx.doi.org/10.1055/s-0040-1710659.23.
Harbeck
N
, Zhang
H
, Barrios
CH
, Saji
S
, Jung
KH
, Hegg
R
, . LBA11 – IMpassion031: Results from a phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
. Ann Oncol
. 2020
;31
(4
):S1142
–215
.24.
Sinn
P
, Brucker
SY
, Budach
W
, . DCIS und Risikoläsionen. In: Leitlinienprogramm Onkologie der AWMF, DKG und DKH, editor. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms
. 2017
; p. 79
–89
.25.
Khan
S
, Diaz
A
, Archer
KJ
, Lehman
RR
, Mullins
T
, Cardenosa
G
, . Papillary lesions of the breast: to excise or observe
. Breast J
. 2018 May
;24
(3
):350
–5
.http://dx.doi.org/10.1111/tbj.12907.<!–Q9: last-page details fetched from PubMed–>26.
Rageth
CJ
, O’Flynn
EAM
, Pinker
K
, Kubik-Huch
RA
, Mundinger
A
, Decker
T
, . Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
. Breast Cancer Res Treat
. 2019 Apr
;174
(2
):279
–96
.27.
DeCensi
A
, Puntoni
M
, Guerrieri-Gonzaga
A
, Caviglia
S
, Avino
F
, Cortesi
L
, . Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia
. J Clin Oncol
. 2019 Jul
;37
(19
):1629
–37
.http://dx.doi.org/10.1200/JCO.18.01779.<!–Q10: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, atl, last-page details fetched from PubMed–>28.
De Nonneville
A
, Jauffret
C
, Gonçalves
A
, Classe
JM
, Cohen
M
, Reyal
F
, . Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer
. Res Treat
. 2019 Jun
;175
(2
):379
–87
.29.
Takada
K
, Kashiwagi
S
, Asano
Y
, Goto
W
, Morisaki
T
, Takahashi
K
, . Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ
. BMC Cancer
. 2020
;20
:513
.http://dx.doi.org/10.1186/s12885-020-07001-1.<!–Q13: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial details fetched from PubMed–>30.
Chua
BH
, Link
E
, Kunkler
I
, Olivotto
I
, Westenberg
AH
, Whelan
T
, , Breast International Group (BIG)-aisbl, Trans Tasman Radiation Oncology Group, Scottish Cancer Trials Breast Group, Canadian Cancer Trials Group, European Organization for Research and Treatment of Cancer, International Breast Cancer Study Group, Cancer Trials Ireland
.. A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
. Abstract GS2-04, 2020 San Antonio Breast Cancer Virtual Symposium, December 8–11, 2020, San Antonio, Texas, DOI: 10.1158/1538-7445.SABCS20-GS2-04 (published February 2021)
. 2020
.31.
Strnad
V
, Krug
D
, Sedlmayer
F
, Piroth
MD
, Budach
W
, Baumann
R
, . Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guideline for partial-breast irradiation
. Strahlenther Onkol
. 2020 Sep
;196
(9
):749
–63
.32.
Sestak
I
, Cuzick
J
, Bonanni
B
, Bundred
B
, Levy
C
, Loibl
S
, . 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ
. Abstract GS2-02, 2020 Virtual San Antonio Breast Cancer Symposium, December 8–11, 2020
. 2020
.33.
Hu
X
, Li
S
, Jiang
Y
, Wei
W
, Ji
Y
, Li
Q
, . Intraoperative ultrasound-guided lumpectomy versus wire-guided excision for nonpalpable breast cancer
. J Int Med Res
. 2020 Jan
;48
(1
):300060519896707
.http://dx.doi.org/10.1177/0300060519896707.<!–Q26: author2initial, author3initial, author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, first-page details fetched from PubMed–>34.
Giuliano
AE
, Ballman
KV
, McCall
L
, Beitsch
PD
, Brennan
MB
, Kelemen
PR
, . Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
. JAMA
. 2017 Sep
;318
(10
):918
–26
.35.
Donker
M
, van Tienhoven
G
, Straver
ME
, Meijnen
P
, van de Velde
CJ
, Mansel
RE
, . Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
. Lancet Oncol
. 2014
;15
(12
):1303
–10
.http://dx.doi.org/10.1016/S1470-2045(14)70460-7.<!–Q14: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>36.
Moo
TA
, Edelweiss
M
, Hajiyeva
S
, Stempel
M
, Raiss
M
, Zabor
EC
, . Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection
. Ann Surg Oncol
. 2018
;25
(6
):1488
–94
.http://dx.doi.org/10.1245/s10434-018-6429-2.<!–Q15: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>37.
Tee
SR
, Devane
LA
, Evoy
D
, Rothwell
J
, Geraghty
J
, Prichard
RS
, . Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer
. Br J Surg
. 2018 Nov
;105
(12
):1541
–52
.http://dx.doi.org/10.1002/bjs.10986.<!–Q16: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>38.
Caudle
AS
, Yang
WT
, Krishnamurthy
S
, Mittendorf
EA
, Black
DM
, Gilcrease
MZ
, . Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection
. J Clin Oncol
. 2016 Apr
;34
(10
):1072
–8
.39.
Weber
WP
, Soysal
SD
, El-Tamer
M
, Sacchini
V
, Knauer
M
, Tausch
C
, . First international consensus conference on standardization of oncoplastic breast conserving surgery
. Breast Cancer Res Treat
. 2017 Aug
;165
(1
):139
–49
.http://dx.doi.org/10.1007/s10549-017-4314-5.<!–Q18: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>40.
Weber
WP
, Morrow
M
, Boniface
J
, Pusic
A
, Montagna
G
, Kappos
EA
, . Knowledge gaps in oncoplastic breast surgery
. Lancet Oncol
. 2020 Aug
;21
(8
):e375
–85
.http://dx.doi.org/10.1016/S1470-2045(20)30084-X.<!–Q19: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>41.
Hai
Y
, Chong
W
, Lazar
MA
. Extended prophylactic antibiotics for mastectomy with immediate breast reconstruction: a meta-analysis
. Plast Reconstr Surg Glob Open
. 2020 Jan
;8
(1
):e2613
.42.
Hallberg
H
, Rafnsdottir
S
, Selvaggi
G
, Strandell
A
, Samuelsson
O
, Stadig
I
, . Benefits and risks with acellular dermal matrix (ADM) and mesh support in immediate breast reconstruction: a systematic review and meta-analysis
. J Plast Surg Hand Surg
. 2018 Jun
;52
(3
):130
–47
.http://dx.doi.org/10.1080/2000656X.2017.1419141.<!–Q20: author2surname, author2initial, author3surname, author3initial, author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>43.
Scomacao
I
, Cummins
A
, Roan
E
, Duraes
EFR
, Djohan
R
. The use of surgical site drains in breast reconstruction: a systematic review
. J Plast Reconstr Aesthet Surg
. 2020 Apr
;73
(4
):651
–62
.http://dx.doi.org/10.1016/j.bjps.2019.11.019.<!–Q21: last-page details fetched from PubMed–>44.
Untch
M
, Jackisch
C
, Schneeweiss
A
, Schmatloch
S
, Aktas
B
, Denkert
C
, . NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto
. J Clin Oncol
. 2019 Sep
;37
(25
):2226
–34
.http://dx.doi.org/10.1200/JCO.18.01842.<!–Q25: author1initial, author2initial, author3initial, author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>45.
Kuemmel
S
, Gluz
O
, Christgen
M
, Potenberg
J
, Hackmann
, von Schumann
R
, . Efficacy of response- and toxicity-guided neoadjuvant chemotherapy in elderly early breast cancer patients: Results of WSG ADAPT elderly sub-trial
. Cancer Res
. 2020
;80
(4 Suppl l
):abstract P2-16-05.46.
JU
Blohmer
, Link
T
, Kümmel
S
, Untch
M
, Just
M
, Fasching
PA
, . Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer – first results of the GeparX study
. Cancer Res
. 2020
;80
(4 Suppl l
):abstract GS3-01.47.
Schmid
P
, Cortes
J
, Pusztai
L
, McArthur
H
, Kümmel
S
, Bergh
J
, .; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer
. N Engl J Med
. 2020
;382
(9
):810
–21
.48.
Mittendorf
EA
, Zhang
H
, Barrios
CH
, Saji
S
, Jung
KH
, Hegg
R
, . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
. Lancet
. 2020
;396
(10257
):1090
–100
.http://dx.doi.org/10.1016/S0140-6736(20)31953-X.<!–Q22: last-page details fetched from PubMed–>49.
O’Shaughnessy
JA
, Johnston
S
, Harbeck
N
, Toi
M
, Im
YH
, Reinisch
M
, . Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk EBC
. San Antonio Breast Cancer Symposium
. 2020
. GS1-01.50.
Mayer
EL
, Dueck
AC
, Martin
M
, Rubovszky
G
, Burstein
HJ
, Bellet-Ezquerra
M
, . Palbociclib with adjuvant endocrine therapy in EBC (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
. Lancet Oncol
. 2021
;22
(2
):212
–22
.51.
Loibl
S
, Marmé
F
, Martin
M
, Untch
M
, Bonnefoi
H
, Kim
SB
, . Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): first results from PENELOPE-B
. San Antonio Breast Cancer Symposium
. 2020
. GS1-02.52.
Chan
A
, Moy
B
, Mansi
J
, Ejlertsen
B
, Holmes
FA
, Chia
S
, .; ExteNET Study Group. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
. Clin Breast Cancer
. 2021
;21
(1
):80
–91
.e7.53.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
; Peto
R
, Davies
C
, Godwin
J
, Gray
R
, Pan
HC
, Clarke
M
, . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
. Lancet
. 2012
;379
(9814
):432
–44
.54.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
.. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
. Lancet
. 2019
;393
(10179
):1440
–52
.55.
Schneeweiss
A
, Möbus
V
, Tesch
H
, Klare
P
, Denkert
C
, Kast
K
, . Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
. Ann Oncol
. 2020
;31
(Suppl 4
):S303
–4
.56.
Wang
X
, Wang
SS
, Huang
H
, Cai
L
, Zhao
L
, Peng
RJ
, . Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial
. JAMA
. 2021 Jan
;325
(1
):50
–8
.http://dx.doi.org/10.1001/jama.2020.23370.<!–Q23: author1initial, author2initial, author3initial, author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>57.
Yu
KD
, Ye
FG
, He
M
, Fan
L
, Ma
D
, Mo
M
, . Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial
. JAMA Oncol
. 2020 Sep
;6
(9
):1390
–6
.58.
Gluz
O
, Nitz
U
, Liedtke
C
, Christgen
M
, Grischke
EM
, Forstbauer
H
, . Comparison of neoadjuvant Nab-paclitaxel + carboplatin vs Nab-paclitaxel + gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results
. J Natl Cancer Inst
. 2018 Jun
;110
(6
):628
–37
.http://dx.doi.org/10.1093/jnci/djx258.Nitz U<!–Q24: author2surname, author2initial, author3surname, author3initial, author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>59.
Villegas
S
, Lederer
B
. Similarities between low hormone receptor positive and hormone receptor negative breast cancer: an analysis of 4366 patients from multicenter clinical trials
. San Antonio Breast Cancer Symposium
. 2018
. P2-08-10.60.
Viale
G
, Regan
MM
, Maiorano
E
, Mastropasqua
MG
, Dell’Orto
P
, Rasmussen
BB
, . Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
. J Clin Oncol
. 2007
;25
(25
):3846
–52
.http://dx.doi.org/10.1200/JCO.2007.11.9453.<!–Q27: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, last-page details fetched from PubMed–>61.
Francis
PA
, Pagani
O
, Fleming
GF
, Walley
BA
, Colleoni
M
, Láng
I
, .; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer
. N Engl J Med
. 2018
;379
:122
–37
.62.
Mayer
EL
, Dueck
AC
, Martin
M
, Rubovszky
G
, Burstein
HJ
, Bellet-Ezquerra
M
, . Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
. Lancet Oncol
. 2021
;22
(2
):212
–22
.http://dx.doi.org/10.1016/S1470-2045(20)30642-2.<!–Q28: last-page details fetched from PubMed–>63.
Loibl
S
, Marmé
F
, Martin
M
, Untch
M
, Bonnefoi
H
, Kim
S-B
, . Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): first results from PENELOPE-B
. San Antonio Breast Cancer Symposium
. 2020
. GS1-02.64.
Johnston
SRD
, Harbeck
N
, Hegg
R
, Toi
M
, Martin
M
, Shao
ZM
, . Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2–, node-positive, high-risk, early breast cancer (monarchE)
. J Clin Oncol
. 2020
;38
:3987–98
.http://dx.doi.org/10.1200/JCO.20.02514.<!–Q29: vol, first-page details fetched from PubMed–>65.
Brunt
AM
, Haviland
JS
, Sydenham
M
, Agrawal
RK
, Algurafi
H
, Alhasso
A
, . Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for EBC
. J Clin Oncol
. 2020 Oct
;38
(28
):3261
–72
.66.
Brunt
AM
, Haviland
JS
, Wheatley
DA
, Sydenham
MA
, Alhasso
A
, Bloomfield
DJ
, . Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
. Lancet
. 2020 May
;395
(10237
):1613
–26
.67.
Choi
KH
, Ahn
SJ
, Jeong
JU
, Yu
M
, Kim
JH
, Jeong
BK
, . Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in EBC: a randomized clinical trial of KROG 15-03
. Radiother Oncol
. 2020 Sep
;154
:179
–86
.68.
Hörner-Rieber
J
, Forster
T
, Hommertgen
A
, Haefner
MF
, Arians
N
, König
L
, . Intensity modulated radiation therapy (IMRT) with simultaneously integrated boost shortens treatment time and is noninferior to conventional radiation therapy followed by sequential boost in adjuvant breast cancer treatment: results of a large randomized phase III trial (IMRT-MC2 Trial)
. Int J Radiat Oncol Biol Phys
. 2021 Apr
;109
(5
):1311
–24
.http://dx.doi.org/10.1016/j.ijrobp.2020.12.005.<!–Q30: author1initial, author2initial, author3initial, author4initial, author5initial, author6initial, stl details fetched from Crossref–>69.
Wedam
S
, Fashoyin-Aje
L
, Bloomquist
E
, Tang
S
, Sridhara
R
, Goldberg
KB
, . FDA Approval Summary: Palbociclib for male patients with metastatic breast cancer
. Clin Cancer Res
. 2020
;26
:1208
–12
.http://dx.doi.org/10.1158/1078-0432.CCR-19-2580.<!–Q31: last-page details fetched from PubMed–>70.
Spanheimer
PM
, Murray
MP
, Zabor
EC
, Stempel
M
, Morrow
M
, Van Zee
KJ
, . Long-term outcomes after surgical treatment of malignant/borderline phyllodes tumors of the breast
. Ann Surg Oncol
. 2019
;26
:2136
–43
.http://dx.doi.org/10.1245/s10434-019-07210-4.<!–Q32: last-page details fetched from PubMed–>71.
Rosenberger
LH
, Thomas
SM
, Nimbkar
SN
, Hieken
TJ
, Ludwig
KK
, Jacobs
LK
, . Contemporary multi-institutional cohort of 550 cases of phyllodes tumors (2007–2017) demonstrates a need for more individualized margin guidelines
. J Clin Oncol
. 2021
;39
(3
):178
–89
.http://dx.doi.org/10.1200/JCO.20.02647.<!–Q33: iss, last-page details fetched from PubMed–>72.
Corso
G
, Frassoni
S
, Girardi
A
, De Camilli
E
, Montagna
E
, Intra
M
, . Metaplastic breast cancer: prognostic and therapeutic considerations
. J Surg Oncol
. 2021
;123
(1
):61
–70
.http://dx.doi.org/10.1002/jso.26248.<!–Q38: iss details fetched from PubMed–>73.
Rakha
EA
, Badve
S
, Eusebi
V
, Reis-Filho
JS
, Fox
SB
, Dabbs
DJ
, . Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management
. Histopathology
. 2016
;68
:45
–56
.74.
Leon-Ferre
RA
, Novotny
PJ
, Wolfe
EG
, Faubion
SS
, Ruddy
KJ
, Flora
D
, . Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603)
. JNCI Cancer Spectr
. 2019
;4
:pkz088
.75.
Heudel
PE
, van Praagh-Doreau
I
, Duvert
B
, Cauvin
I
, Hardy-Bessard
AC
, Jacquin
JP
, . Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial
. Support Care Cancer
. 2019
;27
:1879
–89
.76.
Lahart
IM
, Metsios
GS
, Nevill
AM
, Carmichael
AR
. Physical activity for women with breast cancer after adjuvant therapy
. Cochrane Database Syst Rev
. 2018
;1
:CD011292
.77.
Hershman
DL
, Unger
JM
, Greenlee
H
, Capodice
JL
, Lew
DL
, Darke
AK
, . Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial
. JAMA
. 2018
;320
:167
–76
.78.
Athanasiou
S
, Pitsouni
E
, Douskos
A
, Salvatore
S
, Loutradis
D
, Grigoriadis
T
. Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis
. Lasers Med Sci
. 2020 Feb
;35
(1
):1
–11
.79.
S3-Leitlinie: Supportive Therapie bei onkologischen PatientInnen – Langversion 1.3, Februar 2020, AWMF Registernummer: 032/054OL. http://leitlinienprogrammonkologie.de/Supportive-Therapie.95.0.html.
80.
Liu
Z
, Jiang
L
, Liang
G
, Song
E
, Jiang
W
, Zheng
Y
, . Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management
. J Viral Hepat
. 2017
;24
(7
):561
–72
.http://dx.doi.org/10.1111/jvh.12672.<!–Q34: last-page details fetched from PubMed–>81.
Hashimoto
H
, Abe
M
, Tokuyama
O
, Mizutani
H
, Uchitomi
Y
, Yamaguchi T
, . Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
. Lancet Oncol
. 2020
;21
(2
):242
–9
.82.
Slimano
F
, Netzer
F
, Borget
I
, Lemare
F
, Besse
B
. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy
. Int J Clin Pharm
. 2018 Oct
;40
(5
):1265
–71
.http://dx.doi.org/10.1007/s11096-018-0649-1.<!–Q35: last-page details fetched from PubMed–>83.
Curigliano
G
, Lenihan
D
, Fradley
M
, Ganatra
S
, Barac
A
, Blaes
A
, . Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
. Ann Oncol
. 2020
;31
:171
–90
.http://dx.doi.org/10.1016/j.annonc.2019.10.023.<!–Q36: author4surname, author4initial, author5surname, author5initial, author6surname, author6initial, stl, last-page details fetched from PubMed–>84.
Shah
C
, Ahlawat
S
, Khan
A
, Tendulkar
RD
, Wazer
DE
, Shah
SS
, . The role of MRI in the follow-up of women undergoing breast-conserving therapy
. Am J Clin Oncol
. 2016 Jun
;39
(3
):314
–9
.85.
Runowicz
CD
, Leach
CR
, Henry
NL
, Henry
KS
, Mackey
HT
, Cowens-Alvarado
RL
, . American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline
. CA Cancer J Clin
. 2016
;66
:43
–73
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended...
© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.